Skip to main content

OS Therapies Inc

Data quality: 83%
OSTX
NYSE Manufacturing Chemicals
$1.34
▲ $0.09 (6.80%)
Mkt Cap: 54.02 M
Price
$1.34
Mkt Cap
54.02 M
Day Range
$1.23 — $1.35
52-Week Range
$1.12 — $2.57
Volume
1,156,591
Open $1.25
50D / 200D Avg
$1.40
4.34% below
50D / 200D Avg
$1.74
23.09% below

Quick Summary

Key Takeaways

Debt/Equity of 0.03 — conservative balance sheet
Negative free cash flow of -14.24 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-670.19%
Below sector avg (-53.41%)
ROIC-382.41%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.03
Below sector avg (0.31)
Current Ratio0.56
Interest Coverage-13.99

Valuation

PE (TTM)
-1.88
Below sector avg (-1.48)
P/B Ratio14.85
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.9 -1.5
P/B 14.9 1.6
ROE % -670.2 -53.4
Net Margin % -41.5
Rev Growth 5Y % 1.8
D/E 0.0 0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -28.75 M
ROE -670.19% ROA -298.53%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14.24 M
ROIC -382.41% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.03 Current Ratio 0.56
Interest Coverage -13.99 Asset Turnover N/A
Working Capital -1.82 M Tangible Book Value -3.23 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.88 Forward P/E N/A
P/B Ratio 14.85 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -26.36%
Market Cap 54.02 M Enterprise Value 54.12 M
Per Share
EPS (Diluted TTM) -0.98 Revenue / Share N/A
FCF / Share -0.35 OCF / Share -0.35
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 49.52%
SBC-Adj. FCF -16.90 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue
Net Income -28.75 M -8.88 M
EPS (Diluted) -0.98 -0.88
Gross Profit
Operating Income -28.71 M -6.81 M
EBITDA
R&D Expenses 16.36 M 2.84 M
SG&A Expenses
D&A 363,085.0
Interest Expense 2.05 M 2.05 M
Income Tax

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 6.84 M 5.54 M
Total Liabilities 11.86 M 4.73 M
Shareholders' Equity -6.10 M -5.24 M
Total Debt 100,000.0 100,000.0
Cash & Equivalents
Current Assets 332,912.0 5.53 M
Current Liabilities 11.76 M 4.63 M